Techno-Science.net on MSN

What if Our Mucous Membranes Held a Key to Slowing HIV?

In an article published in Mucosal Immunology, scientists show that IgA antibodies present in mucous membranes play a key ...
FierceBiotech

Artiva sets out $135M IPO plans to push NK cell therapy through trials

Artiva Biotherapeutics is hoping to rake in up to $135 million from a planned IPO, with the proceeds ear-marked for automimmune clinical trials for a lead allogeneic natural killer (NK) cell therapy.
FierceBiotech

Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy

Artiva Biotherapeutics has become the latest biotech to set out IPO ambitions for the summer, as the allogeneic natural killer (NK) cell therapy company pushes its lead program through automimmune ...
Seeking Alpha

ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma

All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor ...
Healio

CAR-NK cell approach achieves ‘efficacy, persistence and super safety’ in lupus

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super ...
Nasdaq

ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL

Immunotherapy innovator ImmunityBio (IBRX) announced that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the ...
Medical Xpress

Experimental drug blocks key protein to trigger cancer cell self-destruction in lung tumors

NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth. The process, called ferroptosis, evolved to let the body ...